Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Cash (2016 - 2025)

Historic Change in Cash for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $22.4 million.

  • Corcept Therapeutics' Change in Cash rose 15736.12% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 14767.15%. This contributed to the annual value of -$7.9 million for FY2024, which is 11139.23% down from last year.
  • As of Q3 2025, Corcept Therapeutics' Change in Cash stood at $22.4 million, which was up 15736.12% from $12.9 million recorded in Q2 2025.
  • Corcept Therapeutics' Change in Cash's 5-year high stood at $233.6 million during Q1 2023, with a 5-year trough of -$127.6 million in Q2 2023.
  • In the last 5 years, Corcept Therapeutics' Change in Cash had a median value of -$742000.0 in 2021 and averaged $2.6 million.
  • In the last 5 years, Corcept Therapeutics' Change in Cash skyrocketed by 210768.19% in 2022 and then tumbled by 50663.89% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Change in Cash (Quarter) stood at -$17.1 million in 2021, then soared by 194.23% to $16.1 million in 2022, then skyrocketed by 47.65% to $23.8 million in 2023, then plummeted by 140.52% to -$9.6 million in 2024, then surged by 332.68% to $22.4 million in 2025.
  • Its Change in Cash stands at $22.4 million for Q3 2025, versus $12.9 million for Q2 2025 and -$37.8 million for Q1 2025.